Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting

References

• Charles A. The evolution of a migraine attack - a review of recent evidence. Headache. 2013 Feb;53(2):413–419.
   PubMed Web of Science ®Google Scholar
• de Tommaso M, Ambrosini A, Brighina F, et al. Altered processing of sensory stimuli in patients with migraine. Nat Rev Neurol. 2014 Mar;10(3):144–155.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017 Apr;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache S. The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629–808.
   PubMed Web of Science ®Google Scholar
• Disease GBD, Injury I, Prevalence C. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep 16;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018 Apr;58(4):496–505.
   PubMed Web of Science ®Google Scholar
• Russell FA, King R, Smillie SJ, et al. Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev. 2014 Oct;94(4):1099–1142.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019 Mar;39(3):366–373.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Ekman R, Jansen I, et al. Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J Cereb Blood Flow Metab. 1987 Dec;7(6):720–728.
   PubMed Web of Science ®Google Scholar
• Messlinger K, Hanesch U, Baumgartel M, et al. Innervation of the dura mater encephali of cat and rat: ultrastructure and calcitonin gene-related peptide-like and substance P-like immunoreactivity. Anat Embryol (Berl). 1993 Sep;188(3):219–237.
   PubMedGoogle Scholar
• Eftekhari S, Salvatore CA, Calamari A, et al. Differential distribution of calcitonin gene-related peptide and its receptor components in the human trigeminal ganglion. Neuroscience. 2010 Aug 25;169(2):683–696.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Eftekhari S, Salvatore CA, et al. Cerebellar distribution of calcitonin gene-related peptide (CGRP) and its receptor components calcitonin receptor-like receptor (CLR) and receptor activity modifying protein 1 (RAMP1) in rat. Mol Cell Neurosci. 2011 Jan;46(1):333–339.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Edvinsson L. Calcitonin gene-related peptide (CGRP) and its receptor components in human and rat spinal trigeminal nucleus and spinal cord at C1-level. BMC Neurosci. 2011 Nov 10;12:112.
   PubMed Web of Science ®Google Scholar
• Messlinger K. The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system. J Headache Pain. 2018 Mar 12;19(1):22.
   PubMedGoogle Scholar
• Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993 Jan;33(1):48–56.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990 Aug;28(2):183–187.
   PubMed Web of Science ®Google Scholar
• Cady RK, Vause CV, Ho TW, et al. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache. 2009 Oct;49(9):1258–1266.
   PubMed Web of Science ®Google Scholar
• Kamm K, Straube A, Ruscheweyh R. Calcitonin gene-related peptide levels in tear fluid are elevated in migraine patients compared to healthy controls. Cephalalgia. 2019 Oct;39(12):1535–1543.
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Jakab B, et al. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005 Mar;25(3):179–183.
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, Lipka K, Ashina M, et al. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005 Oct;58(4):561–568.
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollon E, Larrosa D, Ramon C, et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013 Oct 1;81(14):1191–1196.
   PubMed Web of Science ®Google Scholar
• van Dongen RM, Zielman R, Noga M, et al. Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia. 2017 Jan;37(1):49–63.
   PubMed Web of Science ®Google Scholar
• Asghar MS, Hansen AE, Amin FM, et al. Evidence for a vascular factor in migraine. Ann Neurol. 2011 Apr;69(4):635–645.
   PubMed Web of Science ®Google Scholar
• Guo S, Vollesen AL, Olesen J, et al. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain. 2016 Dec;157(12):2773–2781.
   PubMed Web of Science ®Google Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010 Oct;30(10):1179–1186.
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002 Feb;22(1):54–61.
   PubMed Web of Science ®Google Scholar
• Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 2012 Jan;32(2):140–149.
   PubMed Web of Science ®Google Scholar
• Petersen KA, Lassen LH, Birk S, et al. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther. 2005 Mar;77(3):202–213.
   PubMed Web of Science ®Google Scholar
• Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain. 2014 Mar;137(Pt 3):650–651.
   PubMedGoogle Scholar
• Guo S, Ashina M, Olesen J, et al. The effect of sodium nitroprusside on cerebral hemodynamics and headache in healthy subjects. Cephalalgia. 2013 Apr;33(5):301–307.
   PubMed Web of Science ®Google Scholar
• Rahmann A, Wienecke T, Hansen JM, et al. Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine. Cephalalgia. 2008 Mar;28(3):226–236.
   PubMed Web of Science ®Google Scholar
• Caughey GH, Leidig F, Viro NF, et al. Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther. 1988 Jan;244(1):133–137.
   PubMed Web of Science ®Google Scholar
• Messlinger K, Russo AF. Current understanding of trigeminal ganglion structure and function in headache. Cephalalgia. 2018 Jan;1:333102418786261.
   Google Scholar
• Raddant AC, Russo AF. Calcitonin gene-related peptide in migraine: intersection of peripheral inflammation and central modulation. Expert Rev Mol Med. 2011 Nov;29(13):e36.
   Google Scholar
• Edvinsson JCA, Warfvinge K, Krause DN, et al. C-fibers may modulate adjacent Adelta-fibers through axon-axon CGRP signaling at nodes of Ranvier in the trigeminal system. J Headache Pain. 2019 Nov 12;20(1):105.
   PubMed Web of Science ®Google Scholar
• Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci. 2010 Feb;13(2):239–245.
   PubMed Web of Science ®Google Scholar
• Delwig A, Logan AM, Copenhagen DR, et al. Light evokes melanopsin-dependent vocalization and neural activation associated with aversive experience in neonatal mice. PLoS One. 2012;7(9):e43787.
   PubMed Web of Science ®Google Scholar
• Summ O, Charbit AR, Andreou AP, et al. Modulation of nocioceptive transmission with calcitonin gene-related peptide receptor antagonists in the thalamus. Brain. 2010 Sep;133(9):2540–2548.
   PubMed Web of Science ®Google Scholar
• de Lacalle S, Saper CB. Calcitonin gene-related peptide-like immunoreactivity marks putative visceral sensory pathways in human brain. Neuroscience. 2000;100(1):115–130.
   PubMed Web of Science ®Google Scholar
• Mehnert J, May A. Functional and structural alterations in the migraine cerebellum. J Cereb Blood Flow Metab. 2019 Apr;39(4):730–739.
   PubMed Web of Science ®Google Scholar
• Mehnert J, Schulte L, Timmann D, et al. Activity and connectivity of the cerebellum in trigeminal nociception. Neuroimage. 2017 Apr;15(150):112–118.
   Google Scholar
• Russo AF. Calcitonin gene-related peptide (CGRP): a new target for migraine. Annu Rev Pharmacol Toxicol. 2015;55:533–552.
   PubMed Web of Science ®Google Scholar
• Palmiter RD. The parabrachial nucleus: CGRP neurons function as a general alarm. Trends Neurosci. 2018 May;41(5):280–293.
   PubMed Web of Science ®Google Scholar
• Campos CA, Bowen AJ, Roman CW, et al. Encoding of danger by parabrachial CGRP neurons. Nature. 2018 Mar 29;555(7698):617–622.
   PubMed Web of Science ®Google Scholar
• Rodriguez E, Sakurai K, Xu J, et al. A craniofacial-specific monosynaptic circuit enables heightened affective pain. Nat Neurosci. 2017 Dec;20(12):1734–1743.
   PubMed Web of Science ®Google Scholar
• Mathew NT, Kailasam J, Seifert T. Clinical recognition of allodynia in migraine. Neurology. 2004 Sep 14;63(5):848–852.
   PubMed Web of Science ®Google Scholar
• De Logu F, Landini L, Janal MN, et al. Migraine-provoking substances evoke periorbital allodynia in mice. J Headache Pain. 2019 Feb 14;20(1):18.
   PubMedGoogle Scholar
• Avona A, Burgos-Vega C, Burton MD, et al. Dural calcitonin gene-related peptide produces female-specific responses in rodent migraine models. J Neurosci. 2019 May 29;39(22):4323–4331.
   PubMed Web of Science ®Google Scholar
• Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987 Feb 17;403(2):350–354.
   PubMed Web of Science ®Google Scholar
• Marquez de Prado B, Hammond DL, Russo AF. Genetic enhancement of calcitonin gene-related Peptide-induced central sensitization to mechanical stimuli in mice. J Pain. 2009 Sep;10(9):992–1000.
   PubMed Web of Science ®Google Scholar
• Langford DJ, Bailey AL, Chanda ML, et al. Coding of facial expressions of pain in the laboratory mouse. Nat Methods. 2010 Jun;7(6):447–449.
   PubMed Web of Science ®Google Scholar
• Rea BJ, Wattiez AS, Waite JS, et al. Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine. Pain. 2018 Nov;159(11):2306–2317.
   PubMed Web of Science ®Google Scholar
• Russo AF, Recober A. Unanswered questions in headache: so what is photophobia, anyway? Headache. 2013 Nov-Dec;53(10):1677–1678.
   PubMedGoogle Scholar
• Recober A, Kuburas A, Zhang Z, et al. Role of calcitonin gene-related peptide in light-aversive behavior: implications for migraine. J Neurosci. 2009 Jul 8;29(27):8798–8804.
   PubMed Web of Science ®Google Scholar
• Kaiser EA, Kuburas A, Recober A, et al. Modulation of CGRP-induced light aversion in wild-type mice by a 5-HT(1B/D) agonist. J Neurosci. 2012 Oct 31;32(44):15439–15449.
   PubMed Web of Science ®Google Scholar
• Mason BN, Kaiser EA, Kuburas A, et al. Induction of migraine-like photophobic behavior in mice by both peripheral and central CGRP mechanisms. J Neurosci. 2017 Jan 4;37(1):204–216.
   PubMed Web of Science ®Google Scholar
• Recober A, Kaiser EA, Kuburas A, et al. Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. Neuropharmacology. 2010 Jan;58(1):156–165.
   PubMed Web of Science ®Google Scholar
• Chan KY, Edvinsson L, Eftekhari S, et al. Characterization of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) in human isolated coronary arteries. J Pharmacol Exp Ther. 2010 Sep 1;334(3):746–752.
   PubMed Web of Science ®Google Scholar
• Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005 Feb;25(2):139–147.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Tepper SJ, Watkins PB, et al. Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: randomized, placebo-controlled trial in healthy adults. Cephalalgia. 2019 Dec;39(14):1753–1761.
   PubMed Web of Science ®Google Scholar
• Conway CM, Croop R, Dubowchik GM, et al. Cardiovascular safety of rimegepant 75 mg in 3 randomized clinical trials and systematic evaluations from in vitro ex vivo and in vivo nonclinical assays. American Headache Society Annual Scientific Meeting; Philadelphia, PA: 2019.
   Google Scholar
• Sacco S, Kurth T. Migraine and the risk for stroke and cardiovascular disease. Curr Cardiol Rep. 2014 Sep;16(9):524.
   PubMed Web of Science ®Google Scholar
• Negro A, Martelletti P. Gepants for the treatment of migraine. Expert Opin Investig Drugs. 2019 Jun;28(6):555–567.
   PubMed Web of Science ®Google Scholar
• Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 Mar 11;350(11):1104–1110.
   PubMed Web of Science ®Google Scholar
• Connor KM, Aurora SK, Loeys T, et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache. 2011 Jan;51(1):73–84.
   PubMed Web of Science ®Google Scholar
• Connor KM, Shapiro RE, Diener HC, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009 Sep 22;73(12):970–977.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Martin V, Lipton RB, et al. Randomized controlled study of telcagepant plus ibuprofen or acetaminophen in migraine. Headache. 2011 Apr;51(4):533–543.
   PubMed Web of Science ®Google Scholar
• Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology. 2014 Sep 9;83(11):958–966.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (Telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet. 2008 Dec 20;372(9656):2115–2123.
   PubMed Web of Science ®Google Scholar
• Ho TW, Ho AP, Ge YJ, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for prevention of headache in women with perimenstrual migraine. Cephalalgia. 2016 Feb;36(2):148–161.
   PubMed Web of Science ®Google Scholar
• Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008 Apr 15;70(16):1304–1312.
   PubMed Web of Science ®Google Scholar
• Ho AP, Dahlof CG, Silberstein SD, et al. Randomized, controlled trial of telcagepant over four migraine attacks. Cephalalgia. 2010 Dec;30(12):1443–1457.
   PubMed Web of Science ®Google Scholar
• Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia. 2011 Apr;31(6):712–722.
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlof C, et al. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia. 2011 Apr;31(5):573–584.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019 Jul 11;381(2):142–149.
   PubMed Web of Science ®Google Scholar
• Study to evaluate the PK of BMS-927711 in patient with migraine during acute migraine and non-migraine condition. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/ct2/show/NCT01445067
   Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019 Dec 5;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of Ubrogepant vs Placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019 Nov 19;322(19):1887–1898.
   PubMed Web of Science ®Google Scholar
• Extension study to evaluate the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with episodic migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/ct2/show/NCT03939312
   Google Scholar
• To evaluate the safety and tolerability of treatment with atogepant 60 mg daily for the prevention of migraine in participants with episodic migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/ct2/show/NCT03700320
   Google Scholar
• Efficacy, safety, and tolerability of atogepant for the prevention of chronic migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/ct2/show/NCT03855137
   Google Scholar
• To evaluate the safety and tolerability of atogepant 10mg, 30 mg and 60 mg once a day for the prevention of migraine in participants with episodic migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/ct2/show/NCT03777059
   Google Scholar
• Bigal ME, Dodick DW, Krymchantowski AV, et al. TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology. 2016 Jul 5;87(1):41–48.
   PubMed Web of Science ®Google Scholar
• Bigal ME, Escandon R, Bronson M, et al. Safety and tolerability of LBR-101, a humanized monoclonal antibody that blocks the binding of CGRP to its receptor: results of the Phase 1 program. Cephalalgia. 2014 Jun;34(7):483–492.
   PubMed Web of Science ®Google Scholar
• Cohen JM, Dodick DW, Yang R, et al. Fremanezumab as add-on treatment for patients treated with other migraine preventive medicines. Headache. 2017 Oct;57(9):1375–1384.
   PubMed Web of Science ®Google Scholar
• Cohen-Barak O, Weiss S, Rasamoelisolo M, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects. Cephalalgia. 2018 Nov;38(13):1960–1971.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA. 2018 May 15;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Halker Singh RB, Aycardi E, Bigal ME, et al. Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: post-hoc analyses from phase 2 trials. Cephalalgia. 2019 Jan;39(1):52–60.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017 Nov 30;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Monteith D, Collins EC, Vandermeulen C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody LY2951742 (Galcanezumab) in healthy volunteers. Front Pharmacol. 2017;8:740.
   PubMed Web of Science ®Google Scholar
• Oakes TMM, Skljarevski V, Zhang Q, et al. Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study. Cephalalgia. 2018 May;38(6):1015–1025.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018 Jul;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018 Feb 1;75(2):187–193.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018 Sep 1;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Silberstein S, et al. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial. Cephalalgia. 2019 Aug;39(9):1075–1085.
   PubMed Web of Science ®Google Scholar
• Ashina M, Dodick D, Goadsby PJ, et al. Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology. 2017 Sep 19;89(12):1237–1243.
   PubMed Web of Science ®Google Scholar
• Ashina M, Tepper S, Brandes JL, et al. Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia. 2018 Sep;38(10):1611–1621.
   PubMed Web of Science ®Google Scholar
• de Hoon J, Van Hecken A, Vandermeulen C, et al. Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther. 2018 May;103(5):815–825.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018 May;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallstrom Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017 Nov 30;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jun;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, et al. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014 Feb;34(2):114–125.
   PubMed Web of Science ®Google Scholar
• Safety and efficacy study in adult subjects with acute migraines. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/show/NCT03235479
   Google Scholar
• Open label safety study in acute treatment of migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/show/NCT03266588
   Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737–745.
   PubMed Web of Science ®Google Scholar
• Voss T, Lipton RB, Dodick DW, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016 Aug;36(9):887–898.
   PubMed Web of Science ®Google Scholar
• Efficacy, safety, and tolerability of oral ubrogepant in the acute treatment of migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/show/NCT02828020
   Google Scholar
• An extension study to evaluate the long-term safety and tolerability of ubrogepant in the treatment of migraine. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/show/NCT02873221
   Google Scholar
• Schuster NM, Rapoport AM. Calcitonin gene-related peptide-targeted therapies for migraine and cluster headache: a review. Clin Neuropharmacol. 2017 Jul/Aug;40(4):169–174.
   PubMed Web of Science ®Google Scholar
• Efficacy, safety, and tolerability of multiple dosing regimens of oral atogepant (AGN-241689) in episodic migraine prevention. [cited 2019 Oct 29th]. Available from: https://clinicaltrials.gov/ct2/show/NCT02848326
   Google Scholar
• Goadsby PJ, Dodick DW, Trugman JM, et al. Orally administered atogepant was efficacious, safe, and tolerable for the prevention of migraine: results from a Phase 2b/3 Study (S17.001). Neurology. 2019;92(15Supplement). Available from: https://n.neurology.org/content/92/15_Supplement/S17.001
   Google Scholar
• Bigal ME, Dodick DW, Rapoport AM, et al. Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol. 2015 Nov;14(11):1081–1090.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100–1107.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings EL, et al. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2014 Sep;13(9):885–892.
   PubMed Web of Science ®Google Scholar
• Sun H, Dodick DW, Silberstein S, et al. Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2016 Apr;15(4):382–390.
   PubMed Web of Science ®Google Scholar
• Lionetto L, Curto M, Cisale GY, et al. Fremanezumab for the preventive treatment of migraine in adults. Expert Rev Clin Pharmacol. 2019 Aug;12(8):741–748.
   PubMed Web of Science ®Google Scholar
• Maassen van den Brink A, Rubio-Beltran E, Duncker D, et al. Is CGRP receptor blockade cardiovascularly safe? appropriate studies are needed. Headache. 2018 Sep;58(8):1257–1258.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalon CM, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016 Sep;37(9):779–788.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby PJ, Reuter U, et al. Long-term safety and tolerability of erenumab: three-plus year results from a five-year open-label extension study in episodic migraine. Cephalalgia. 2019 Oct;39(11):1455–1464.
   PubMed Web of Science ®Google Scholar
• Depre C, Antalik L, Starling A, et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache. 2018 May;58(5):715–723.
   PubMed Web of Science ®Google Scholar
• Aradi S, Kaiser E, Cucchiara B. Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a case report. J Stroke Cerebrovasc Dis. 2019 Oct;28(10):104286.
   PubMed Web of Science ®Google Scholar
• Hendrikse ER, Bower RL, Hay DL, et al. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system. Cephalalgia. 2019 Mar;39(3):403–419.
   PubMed Web of Science ®Google Scholar
• Hay DL. CGRP receptor biology: is there more than one receptor? Handb Exp Pharmacol. 2019;255:13–22.
   PubMedGoogle Scholar
• Hay DL, Walker CS. CGRP and its receptors. Headache. 2017 Apr;57(4):625–636.
   PubMed Web of Science ®Google Scholar
• Walker CS, Eftekhari S, Bower RL, et al. A second trigeminal CGRP receptor: function and expression of the AMY1 receptor. Ann Clin Transl Neurol. 2015 Jun;2(6):595–608.
   PubMed Web of Science ®Google Scholar
• Walker CS, Conner AC, Poyner DR, et al. Regulation of signal transduction by calcitonin gene-related peptide receptors. Trends Pharmacol Sci. 2010 Oct;31(10):476–483.
   PubMed Web of Science ®Google Scholar
• Cottrell GS, Padilla B, Pikios S, et al. Post-endocytic sorting of calcitonin receptor-like receptor and receptor activity-modifying protein 1. J Biol Chem. 2007 Apr 20;282(16):12260–12271.
   PubMed Web of Science ®Google Scholar
• Kuwasako K, Shimekake Y, Masuda M, et al. Visualization of the calcitonin receptor-like receptor and its receptor activity-modifying proteins during internalization and recycling. J Biol Chem. 2000 Sep 22;275(38):29602–29609.
   PubMed Web of Science ®Google Scholar
• Yarwood RE, Imlach WL, Lieu T, et al. Endosomal signaling of the receptor for calcitonin gene-related peptide mediates pain transmission. Proc Natl Acad Sci U S A. 2017 Nov 14;114(46):12309–12314.
   PubMed Web of Science ®Google Scholar
• Seck T, Baron R, Horne WC. Binding of filamin to the C-terminal tail of the calcitonin receptor controls recycling. J Biol Chem. 2003 Mar 21;278(12):10408–10416.
   PubMed Web of Science ®Google Scholar
• Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016 Jan;356(1):223–231.
   PubMed Web of Science ®Google Scholar
• Hay DL, Christopoulos G, Christopoulos A, et al. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-d ibromo-4-hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazoliny l) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors–the role of receptor activity modifying protein 1. Mol Pharmacol. 2006 Dec;70(6):1984–1991.
   PubMed Web of Science ®Google Scholar
• Russo AF. Overview of neuropeptides: awakening the senses? Headache. 2017 May;57(Suppl 2):37–46.
   PubMedGoogle Scholar
• Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993 Apr 30;192(2):553–560.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338–350.
   PubMed Web of Science ®Google Scholar
• Christensen CE, Younis S, Deen M, et al. Migraine induction with calcitonin gene-related peptide in patients from erenumab trials. J Headache Pain. 2018 Nov 8;19(1):105.
   PubMedGoogle Scholar
• DosSantos MF, Holanda-Afonso RC, Lima RL, et al. The role of the blood-brain barrier in the development and treatment of migraine and other pain disorders. Front Cell Neurosci. 2014;8:302.
   PubMed Web of Science ®Google Scholar
• Edvinsson L. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. 2015 Aug;80(2):193–199.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Ho TW. CGRP receptor antagonism and migraine. Neurotherapeutics. 2010 Apr;7(2):164–175.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP(8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol. 2007 Mar;150(5):633–640.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Tfelt-Hansen P. The blood-brain barrier in migraine treatment. Cephalalgia. 2008 Dec;28(12):1245–1258.
   PubMed Web of Science ®Google Scholar
• Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? Pain. 2005 May;115(1–2):1–4.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Goadsby PJ, Roon KI, et al. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002 Oct;22(8):633–658.
   PubMed Web of Science ®Google Scholar
• Hostetler ED, Joshi AD, Sanabria-Bohorquez S, et al. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232. J Pharmacol Exp Ther. 2013 Nov;347(2):478–486.
   PubMed Web of Science ®Google Scholar
• Russo AF. Overview of neuropeptides: awakening the senses? Headache. 2017;57(S2):37–46.
   PubMedGoogle Scholar
• Edvinsson L, Tajti J, Szalardy L, et al. PACAP and its role in primary headaches. J Headache Pain. 2018 Mar 9;19(1):21.
   PubMedGoogle Scholar
• Kaiser EA, Russo AF. CGRP and migraine: could PACAP play a role too? Neuropeptides. 2013 Dec;47(6):451–461.
   PubMed Web of Science ®Google Scholar
• Uzar E, Evliyaoglu O, Toprak G, et al. Increased asymmetric dimethylarginine and nitric oxide levels in patients with migraine. J Headache Pain. 2011 Apr;12(2):239–243.
   PubMed Web of Science ®Google Scholar
• Martami F, Razeghi Jahromi S, Togha M, et al. The serum level of inflammatory markers in chronic and episodic migraine: a case-control study. Neurol Sci. 2018 Oct;39(10):1741–1749.
   PubMed Web of Science ®Google Scholar